UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000006333
Receipt number R000007509
Scientific Title Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate and calcium carbonate on FGF23 in hemodialysis patients
Date of disclosure of the study information 2011/09/15
Last modified on 2012/09/13 12:56:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate and calcium carbonate on FGF23 in hemodialysis patients

Acronym

Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate and calcium carbonate on FGF23 in hemodialysis patients

Scientific Title

Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate and calcium carbonate on FGF23 in hemodialysis patients

Scientific Title:Acronym

Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate and calcium carbonate on FGF23 in hemodialysis patients

Region

Japan


Condition

Condition

Chronic kidney disease

Classification by specialty

Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the effect of lanthanum carbonate and calcium carbonate on serum phosphate and FGF23 levels in newly initiated hemodialysis patients with hyperphosphatemia

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Change of serum FGF23 levels

Key secondary outcomes

Serum phosphate level achievement rate as defined by the JSDT guideline

Safety


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Lanthanum carbonate treatment (Follow-up: 3 months)

Interventions/Control_2

Calcium carbonate treatment (Follow-up: 3 months)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Newly initiated hemodialysis patients for within 2 weeks
2) Age >20 years old
3) Patients with written IC

Key exclusion criteria

1) Malignancy of any type at enrollment
2) History of hypersensitivity to any of the ingredients of Lanthanum carbonate or Calcium carbonate
3) Severe hepatic dysfunction
4) Active digestive ulcer, ulcerative colitis, Crohn's disease and constriction of intestine
5) Pregnant or possibly pregnant women
6) Women on lactation
7) Ineligible patients according to the investigator's judgment

Target sample size

40


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yasuhiko Tomino

Organization

Juntendo University Faculty of Medicine

Division name

Division of Nephrology, Department of Internal Medicine

Zip code


Address

2-1-1 Hongo Bunkyo-ku, Tokyo, Japan

TEL

+81-3-3813-3111

Email



Public contact

Name of contact person

1st name
Middle name
Last name Junichiro Nakata

Organization

Juntendo University Faculty of Medicine

Division name

Division of Nephrology, Department of Internal Medicine

Zip code


Address

2-1-1 Hongo Bunkyo-ku, Tokyo, Japan

TEL


Homepage URL


Email

jnakata@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

順天堂大学医学部附属順天堂医院(東京都)


Other administrative information

Date of disclosure of the study information

2011 Year 09 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 08 Month 01 Day

Date of IRB


Anticipated trial start date

2011 Year 08 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 09 Month 12 Day

Last modified on

2012 Year 09 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007509


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name